Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Timing your first automated investment depends on savings goals and risk comfort; starting early can compound gains over time with steady contributions.
15,330 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Adobe has pulled back about 40% from its peak, but new AI-driven products and expanding ARR are reinvigorating the bu...
Apple files a lawsuit against OpenAI over alleged trade-secrets theft. Jim Cramer calls the move heavyweight, signali...
As the 2026 COLA rises to 2.8%, investors turn to steady income stocks that more than cover the gap. A trio of picks ...
Could SpaceX go public and spark a 450% rally? A wall street analyst sees big upside if key growth engines and regula...
As 2026 unfolds, investors eye three key covered call ETFs for steady monthly income. This analysis compares ISPY, JE...
AMD is positioning itself as a robust player across consumer, data center, and AI markets. This article breaks down w...
The latest inflation data good for equities, traders say, as cooler price gains shift the Fed's path. This guide brea...
A 25 percent drop often triggers fear and temptation to buy the dip. This article breaks down IBM s recent results, t...
A regulatory shift hit the live entertainment market, and StubHub stock plummeted this week. This deep dive explains ...
Chevron is expanding its footprint beyond traditional oil and gas as it eyes large-scale power deals. A landmark 2.7 ...
A massive AI spending wave among hyperscalers could redefine markets. Discover why billionaire Bill Ackman is placing...